Simon Quick Advisors LLC Invests $246,000 in Natera, Inc. (NASDAQ:NTRA)

Simon Quick Advisors LLC purchased a new position in shares of Natera, Inc. (NASDAQ:NTRA) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,554 shares of the medical research company’s stock, valued at approximately $246,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Covestor Ltd boosted its holdings in Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 95 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Natera by 32.7% during the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after acquiring an additional 106 shares during the period. Hanseatic Management Services Inc. boosted its stake in shares of Natera by 12.0% in the 4th quarter. Hanseatic Management Services Inc. now owns 998 shares of the medical research company’s stock valued at $158,000 after purchasing an additional 107 shares in the last quarter. Salem Investment Counselors Inc. grew its holdings in shares of Natera by 0.7% in the 4th quarter. Salem Investment Counselors Inc. now owns 16,280 shares of the medical research company’s stock worth $2,577,000 after purchasing an additional 110 shares during the last quarter. Finally, CIBC Asset Management Inc increased its position in shares of Natera by 3.3% during the 3rd quarter. CIBC Asset Management Inc now owns 3,477 shares of the medical research company’s stock worth $441,000 after purchasing an additional 111 shares in the last quarter. 99.90% of the stock is owned by institutional investors.

Natera Trading Down 2.5 %

NTRA opened at $167.61 on Friday. The firm’s fifty day moving average is $166.20 and its two-hundred day moving average is $136.07. The firm has a market cap of $22.13 billion, a PE ratio of -95.23 and a beta of 1.65. Natera, Inc. has a twelve month low of $62.96 and a twelve month high of $183.00. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. During the same quarter last year, the business posted ($0.95) EPS. The firm’s revenue was up 63.9% compared to the same quarter last year. Equities research analysts anticipate that Natera, Inc. will post -1.56 EPS for the current year.

Insider Activity

In other Natera news, insider John Fesko sold 669 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $159.60, for a total value of $106,772.40. Following the sale, the insider now owns 114,142 shares in the company, valued at approximately $18,217,063.20. The trade was a 0.58 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Solomon Moshkevich sold 1,196 shares of the firm’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $118.21, for a total transaction of $141,379.16. Following the transaction, the insider now directly owns 110,695 shares of the company’s stock, valued at $13,085,255.95. This represents a 1.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 249,940 shares of company stock worth $41,094,664 in the last 90 days. Corporate insiders own 7.60% of the company’s stock.

Analysts Set New Price Targets

NTRA has been the topic of several research analyst reports. StockNews.com cut shares of Natera from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. Piper Sandler increased their price target on Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, November 18th. Craig Hallum lifted their price objective on Natera from $121.00 to $157.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. The Goldman Sachs Group increased their target price on Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, October 16th. Finally, Morgan Stanley raised their price objective on shares of Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $162.94.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.